Timothy Webb, DO
Family Medicine · Bellbrook, OHNPI 1154721645
Payments from drug & device makers
Across 2,652 payments — averaging $120.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$311K
- AbbVie$1K
- Amgen$949
- AstraZeneca$742
- Novo Nordisk$629
- Lilly USA, LLC$488
- plus $3K from 31 others
What the payments were for
- Food & beverage$7,604100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 2,133 | $310,908 |
| AbbVie(2 entities) | 103 | $1,361 |
| Amgen | 62 | $949 |
| AstraZeneca | 38 | $742 |
| Novo Nordisk | 46 | $629 |
| Lilly USA, LLC | 34 | $488 |
| Pfizer | 49 | $422 |
| Merck | 29 | $328 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $288 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $258 |
| Amarin Pharma, Inc. | 23 | $250 |
| Bayer | 12 | $232 |
| Boehringer Ingelheim | 14 | $225 |
| Exact Sciences | 9 | $164 |
| Astellas Pharma US Inc | 2 | $142 |
| Phathom Pharmaceuticals, Inc. | 9 | $140 |
| Abbott | 6 | $134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $107 |
| Dexcom, Inc. | 5 | $88 |
| GSK | 5 | $78 |
| Vanda Pharmaceuticals Inc. | 3 | $74 |
| Johnson & Johnson | 5 | $71 |
| Antares Pharma, Inc. | 4 | $62 |
| Teva Pharmaceuticals USA, Inc. | 4 | $52 |
| Axsome Therapeutics, Inc. | 3 | $51 |
| Dynavax Technologies Corporation | 2 | $31 |
| Daiichi Sankyo Inc. | 2 | $28 |
| Gilead | 2 | $27 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $25 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $19 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Adaptive Biotechnologies Corporation | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Novartis | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$318,512 in reported general payments places this provider in the 95th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 52 | $68,629 |
| VraylarCariprazine Hcl | 34 | $52,554 |
| EliquisApixaban | 40 | $44,773 |
| MounjaroTirzepatide | 16 | $30,175 |
| RybelsusSemaglutide | 11 | $24,995 |
| JardianceEmpagliflozin | 16 | $17,880 |
| TrulicityDulaglutide | 11 | $15,753 |
| UbrelvyUbrogepant | 11 | $11,188 |
| LinzessLinaclotide | 11 | $10,018 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $9,497 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $9,261 |
| NamzaricMemantine Hcl/Donepezil Hcl | 11 | $5,807 |
| Lacosamide | 18 | $5,426 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 215 | $5,338 |
| Humalog Kwikpen U-100Insulin Lispro | 13 | $4,533 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $629 | $93,62463 claims |
| AbbVieVraylar, Ubrelvy, Linzess, Namzaric | $1,361 | $79,56767 claims |
| Lilly USA, LLCMounjaro, Trulicity | $488 | $45,92827 claims |
| PfizerEliquis | $422 | $44,77340 claims |
| Boehringer IngelheimJardiance | $225 | $17,88016 claims |
| GSKBreo Ellipta, Incruse Ellipta | $78 | $13,43833 claims |
| AstraZenecaSymbicort | $742 | $4,32819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Bellbrook
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.